Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)

BACKGROUND: The Neo-REGATTA study evaluated the effectiveness and safety of Docetaxel, oxaliplatin, and S-1 (DOS regimen) followed by radical resection vs. chemotherapy in advanced gastric adenocarcinoma patients with single non-curable factor. METHODS: This cohort study prospectively enrolled advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yuehong, Yu, Yiyi, Zheng, Song, Ying, Jie’er, Du, Yi’an, Wang, Yan, Wang, Xuefei, Shen, Zhenbin, Liu, Fenglin, Lv, Minzhi, Sun, Yihong, Liu, Tianshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074668/
https://www.ncbi.nlm.nih.gov/pubmed/37016303
http://dx.doi.org/10.1186/s12885-023-10773-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074668/
https://www.ncbi.nlm.nih.gov/pubmed/37016303
http://dx.doi.org/10.1186/s12885-023-10773-x

Ejemplares similares